# MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B

> **NCT02783833** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 15 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** MMV390048 40mg
- **DRUG:** MMV390048 dose to be determined mg

## Key facts

- **NCT ID:** NCT02783833
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2017-01-16
- **Final completion:** 2017-01-16
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-02-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02783833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02783833, "MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02783833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*